Imetelstat, a novel telomerase inhibiting drug, has been found to induce morphologic, molecular and clinical remissions in some patients with myelofibrosis a Mayo Clinic study has found. The results were presented today at the 2013 American Society of Hematology Annual Meeting in New Orleans.
Drugs that enhance a process called oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor of muscle and other soft tissue. The findings are the latest from the St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project and appear in the December 9 edition of the scientific journal Cancer Cell.
In nearly one-third of patients with Waldenstrom’s Macroglobulinemia, a specific genetic mutation switches on the disease, and a new drug that blocks the defective gene can arrest the disease in animal models, researchers at Dana-Farber Cancer Institute and allied institutions will report at the 2013 annual meeting of the American Society of Hematology (ASH). The finding may open the way to clinical trials of the drug in Waldenstrom’s patients whose tumor cells carry the mutation.
The clinical context of the administration and dosage of antipsychotics may influence their efficacy, reported Philippe Vincent and Édouard Kouassi, from the Institut universitaire en santé mentale de Montréal and Université de Montréal.
Researchers at Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology, Boston Children’s Hospital, and the Massachusetts Institute of Technology are one step closer to an eye drop-free reality with the development of a drug-eluting contact lens designed for prolonged delivery of latanoprost, a common drug used for the treatment of glaucoma, the leading cause of irreversible blindness worldwide.
Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors, according to researchers from Dana-Farber Cancer Institute.
Changes to a key protein amplified its natural ability to counter kidney disease, according to a study published today by researchers at the University of Alabama at Birmingham in the journal Nature Medicine.
Jasco Pharmaceuticals and Roswell Park are sharing research results on use of a novel PIM2 inhibitor to overcome multi-drug resistance at the American Society of Hematology (ASH) Annual Meeting.
For patients with stable coronary artery disease (CAD) who are not experiencing a heart attack and an abnormal stress test, treatment of their narrowed arteries by the common procedure of angioplasty may not provide additional benefits compared to drug therapy alone. This finding results from a survey of more than 4,000 patients with myocardial ischemia, or inadequate circulation, led by cardiologists at Stony Brook University School of Medicine. The survey results are published in the online first edition of JAMA Internal Medicine.
• Glioblastoma is the most common and deadly form of brain cancer. • Drugs target specific mutations on the surface of glioblastoma cells. • Glioblastoma cells are able to eliminate the gene mutation to avoid detection when the targeted drug is present. • When the drug is stopped, tumor cells are able to reacquire the gene mutation, which resensitizes them to the drug.
Sometimes the cure can be worse than the disease. Pharmaceutical drugs are known for their potential side effects, and now researchers have updated an extensive toxicology database so that it can be used to track information about therapeutic drugs and their unintentional toxic effects.
People who identified their medication by shape, size or color instead of name had poorer adherence and an increased risk of hospitalization, finds a recent study in the Journal of Health Communication: International Perspectives.
A study comparing the efficacy and tolerability of two popular osteoporosis drugs, denosumab and zoledronic acid, found that denosumab had a significantly greater effect on increasing spine bone mineral density and zoledronic acid caused more flulike symptoms. These findings were presented recently at the American Society for Bone and Mineral Research’s annual meeting.
Finger pricks may soon be a thing of the past for diabetics. Researchers at Western New England University have created a breathalyzer that may help control blood sugar by measuring the amount of acetone in the breath.
A University of Colorado Cancer Center study published today in the journal Cancer shows that using crizotinib to treat ALK positive non-small cell lung cancer (NSCLC) appears to reduce kidney function when assessed by one of the most commonly used clinical methods.
The development of a probe to measure the body’s immune function could lead to more accurate, individualized doses for cancer patients prescribed nanoparticle-based drugs, according to research conducted at the University of North Carolina.
Dallas, TX – Researchers from the Sinai Center for Thrombosis Research presented findings from a Phase 2a trial substudy that examined the antiplatelet effects of CSL112, a novel apolipoprotein A-I (apo A-I) infusion therapy, at the American Heart Association 2013 Scientific Sessions.
An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.
Combining the drug gemtuzumab ozogamicin (GO) with conventional chemotherapy may improve the outcome of bone marrow transplantation for some children battling high-risk acute myeloid leukemia (AML), according to a study led by St. Jude Children’s Research Hospital.
Research with baboons at the Texas Biomedical Research Institute in San Antonio may help explain why some people who take bone-strengthening drugs like bisphosphonates are at-risk for atypical fractures in the long bones in their legs.
Researchers developed a first-of-its-kind microbicide gel formulation that shows promise for safe vaginal and rectal administration to prevent the sexual transmission of human immunodeficiency virus (HIV).
Results of a Johns Hopkins study may explain why a chemotherapy drug called cyclophosphamide prevents graft-versus-host (GVHD) disease in people who receive bone marrow transplants. The experiments point to an immune system cell that evades the toxic effects of cyclophosphamide and protects patients from a lethal form of GVHD.
In their ongoing quest to develop the latest and most effective drugs for disease treatment, researchers in the University of Kentucky's Center for Pharmaceutical Research and Innovation (CPRI) are looking deep — as in, deep underground.
Researchers find a genetic difference in blood clotting mechanisms, which could help explain some of the racial health disparity in heart disease.
Scientists have identified a pathway that regulates fibrosis, suggesting a possible pharmacologic approach to treat patients with a broad range of fibrotic diseases.
Tricking algae’s biological clock to remain in its daytime setting can dramatically boost the amount of commercially valuable compounds that these simple marine plants can produce when they are grown in constant light.
Chemists develop new way to kill cancer cells resistant to the chemotherapy drug cisplatin.
The key is that metformin doesn’t work to lower blood glucose by directly working on the glucose. It works on reducing harmful fat molecules in the liver, which then allows insulin to work better and lower blood sugar levels.
Nanoscale images, presented at the AVS Meeting in Long Beach, Calif., may provide ‘hole’ story on pore-making antibiotic peptides
The risks of developing kidney failure and a calcium deficiency from the popular osteoporosis drug zoledronic acid are extremely rare, according to researchers at Loyola University Health System (LUHS). These findings were presented earlier this month at the American Society for Bone and Mineral Research’s annual meeting.
MK-3475, an anti-PD1 immunotherapy drug with promising results in advanced trials in melanoma is also showing potential in lung cancer based on preliminary phase 1b data presented at the 15th World Conference on Lung Cancer in Sydney, Australia. By blocking the PD-1 protein, the drug alerts the immune system to attack the cancer. It is generally well tolerated and further trials in lung cancer are currently underway.
More than 1 in 10 Americans take antidepressants, but these medications can take weeks—and for some patients, months—before they begin to alleviate symptoms. Now, scientists from the University of Chicago have discovered that selectively blocking a serotonin receptor subtype induces fast-acting antidepressant effects in mice, indicating a potential new class of therapeutics for depression. The work was published Oct. 29 in Molecular Psychiatry.
An international team led by University of Adelaide researchers has identified the mechanism of pain relief of a new drug for treating Irritable Bowel Syndrome with Constipation (IBS-C), based on nonclinical studies, and quantified its effectiveness in pain relief in human trials.
A University of Colorado Cancer Center study published in the journal PLoS One shows that when colorectal cancer is targeted by the drug bevacizumab (Avastin), tumors may switch dependence from VEGF-A, which is targeted by the drug, to related growth factors in including VEGF-C, VEGF-D and placental growth factor. This change to new growth-factor dependence may allow colorectal cancer to push past bevacizumab’s blockage of VEGF-A to continue to drive tumor growth.
Researchers will soon begin phase IIa clinical trials of TDI-132, a drug that in animal models has shown promise in reducing the inflammation associated with Amyotrophic Lateral Sclerosis.
New research published in JAMA Psychiatry reveals that topiramate, a drug approved by the U.S. Food and Drug Administration (FDA) to treat epilepsy and migraine headaches, also could be the first reliable medication to help treat cocaine dependence.
Using a discovery platform whose components range from yeast cells to human stem cells, Whitehead Institute scientists have identified a novel Parkinson’s disease drug target and a compound capable of repairing neurons derived from Parkinson’s patients.
Treating aggressive lung cancer with the diabetes drug metformin along with radiation and chemotherapy may slow tumor growth and recurrence, suggests new preliminary findings from researchers at the Perelman School of Medicine at the University of Pennsylvania being presented during an oral abstract session October 28 at the 15th World Conference on Lung Cancer.
Highlights • Kidney transplant recipients who discontinue immunosuppressive drugs before conception have a higher rate of live births and a lower rate of birth defects without an increased risk of kidney problems.
Researchers at the University of California, San Diego School of Medicine have discovered a way to effectively deliver staurosporine (STS), a powerful anti-cancer compound that has vexed researchers for more than 30 years due to its instability in the blood and toxic nature in both healthy and cancerous cells.
Researchers at Washington University School of Medicine in St. Louis have created a massive online database that matches thousands of genes linked to cancer and other diseases with drugs that target those genes. Some of the drugs are approved by the U.S. Food and Drug Administration, while others are in clinical trials or just entering the drug development pipeline.
A team led by scientists at The Scripps Research Institute has identified key signaling proteins in the inflammation process that contribute to the development of inflammatory diseases such as rheumatoid arthritis, psoriasis, sepsis and inflammatory bowel diseases.
Using the Food and Drug Administration's Adverse Event Reporting System (FAERS), a hospital electronic health records database, and an animal model, a team of researchers at the Icahn School of Medicine at Mount Sinai report that by adding a second drug to the diabetes drug rosiglitazone, adverse events dropped enormously. That suggests that drugs could be repurposed to improve drug safety, including lowering the risk of heart attacks.
Physician, scientist and specialty pharmaceuticals entrepreneur, Dr. Seth Lederman, can comment on the process of drug reformulation, development, and why investors should look for companies pursuing a 505(b)(2) FDA approval pathway.
Two gene alterations pair up to promote the growth of leukemia cells and their escape from anti-cancer drugs.
SUNY Downstate Medical Center's Sheryl Smith, PhD, has published new findings demonstrating a reproducible pathology that may help shed light on anxiety and mood volatility in methamphetamine dependence.
An Indiana University cancer researcher and his colleagues have discovered new therapeutic targets and drugs for certain types of leukemia or blood cancer.
Scientists from the Florida campus of The Scripps Research Institute have identified a new drug candidate for an inherited form of cancer with no known cure.
The discovery of genetic differences affecting up to a third of the population could take the guesswork out of prescribing the correct dose of 25 percent of drugs currently on the market, researchers say.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right